Literature DB >> 23764397

Piperlongumine inhibits LMP1/MYC-dependent mouse B-lymphoma cells.

Seong-Su Han1, Van S Tompkins, Dong-Ju Son, Natalie L Kamberos, Laura L Stunz, Ahmad Halwani, Gail A Bishop, Siegfried Janz.   

Abstract

Piperlongumine (PL), isolated from the fruit of Long pepper, Piper longum, is a cancer-inhibiting compound that selectively kills tumor cells while sparing their normal counterparts. Here we evaluated the efficacy with which PL suppresses malignant B cells derived from a newly developed, double-transgenic mouse model of human endemic Burkitt lymphoma (BL), designated mCD40-LMP1/iMyc(Eμ). PL inhibited tumor cell proliferation in a concentration-dependent manner and induced apoptosis of neoplastic but not normal B cells. Treatment with PL resulted in downregulation of EBV-encoded LMP1, cellular Myc, constitutive NF-κB activity, and a host of LMP1-Myc-NF-κB-regulated target genes including Aurka, Bcat1, Bub1b, Ccnb1, Chek1, Fancd2, Tfrc and Xrcc6. Of note, p21(Cip1)-encoding Cdkn1a was suppressed independent of changes in Trp53 mRNA levels and p53 DNA-binding activity. Considering the central role of the LMP1-NF-κB-Myc axis in B-lineage neoplasia, these findings further our understanding of the mechanisms by which PL inhibits B-lymphoma and provide a preclinical rationale for the inclusion of PL in new interventions in blood cancers.
Copyright © 2013 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BL; Burkitt lymphoma; Cancer therapy and prevention; Epstein Barr virus; NF-κB; PL; Piperlongumine; Transgenic mouse model of human endemic Burkitt lymphoma; p21-Encoding Cdkn1a

Mesh:

Substances:

Year:  2013        PMID: 23764397      PMCID: PMC3749779          DOI: 10.1016/j.bbrc.2013.06.012

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  36 in total

1.  Inhibition of c-myc expression induces apoptosis of WEHI 231 murine B cells.

Authors:  M Wu; M Arsura; R E Bellas; M J FitzGerald; H Lee; S L Schauer; D H Sherr; G E Sonenshein
Journal:  Mol Cell Biol       Date:  1996-09       Impact factor: 4.272

2.  An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells.

Authors:  D Wang; D Liebowitz; E Kieff
Journal:  Cell       Date:  1985-12       Impact factor: 41.582

3.  Activation of transferrin receptor 1 by c-Myc enhances cellular proliferation and tumorigenesis.

Authors:  Kathryn A O'Donnell; Duonan Yu; Karen I Zeller; Jung-Whan Kim; Frederick Racke; Andrei Thomas-Tikhonenko; Chi V Dang
Journal:  Mol Cell Biol       Date:  2006-03       Impact factor: 4.272

4.  Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice.

Authors:  Sung Sup Park; Joong Su Kim; Lino Tessarollo; James D Owens; Liangping Peng; Seong Su Han; Seung Tae Chung; Ted A Torrey; Wan C Cheung; Roberto D Polakiewicz; Nicole McNeil; Thomas Ried; J Frederic Mushinski; Herbert C Morse; Siegfried Janz
Journal:  Cancer Res       Date:  2005-02-15       Impact factor: 12.701

5.  A GTPase-activating protein binds STAT3 and is required for IL-6-induced STAT3 activation and for differentiation of a leukemic cell line.

Authors:  Yukio Tonozuka; Yukinori Minoshima; Ying Chun Bao; Yuseok Moon; Yohei Tsubono; Tomonori Hatori; Hideaki Nakajima; Tetsuya Nosaka; Toshiyuki Kawashima; Toshio Kitamura
Journal:  Blood       Date:  2004-07-29       Impact factor: 22.113

Review 6.  Regulation of NADPH oxidases: the role of Rac proteins.

Authors:  Peter L Hordijk
Journal:  Circ Res       Date:  2006-03-03       Impact factor: 17.367

7.  Expression of the cytoplasmic tail of LMP1 in mice induces hyperactivation of B lymphocytes and disordered lymphoid architecture.

Authors:  Laura L Stunz; Lisa K Busch; Melissa E Munroe; Curt D Sigmund; Lorraine T Tygrett; Thomas J Waldschmidt; Gail A Bishop
Journal:  Immunity       Date:  2004-08       Impact factor: 31.745

8.  MYC regulation of CHK1 and CHK2 promotes radioresistance in a stem cell-like population of nasopharyngeal carcinoma cells.

Authors:  Wen-Jun Wang; Si-Pei Wu; Jia-Bin Liu; Yong-Sheng Shi; Xue Huang; Qian-Bing Zhang; Kai-Tai Yao
Journal:  Cancer Res       Date:  2012-12-26       Impact factor: 12.701

9.  Molecular and cytological features of the mouse B-cell lymphoma line iMycEmu-1.

Authors:  Seong Su Han; Arthur L Shaffer; Liangping Peng; Seung Tae Chung; Jae Hwan Lim; Sungho Maeng; Joong Su Kim; Nicole McNeil; Thomas Ried; Louis M Staudt; Siegfried Janz
Journal:  Mol Cancer       Date:  2005-11-09       Impact factor: 27.401

10.  Role of Rel-related factors in control of c-myc gene transcription in receptor-mediated apoptosis of the murine B cell WEHI 231 line.

Authors:  H Lee; M Arsura; M Wu; M Duyao; A J Buckler; G E Sonenshein
Journal:  J Exp Med       Date:  1995-03-01       Impact factor: 14.307

View more
  8 in total

1.  Cisplatin sensitivity mediated by NKX2-1 in lung adenocarcinoma is dependent on p53 mutational status via modulating TNFSF10 expression.

Authors:  Ming-Jenn Chen; Po-Ming Chen; Lee Wang; Ching-Ju Shen; Chi-Yi Chen; Huei Lee
Journal:  Am J Cancer Res       Date:  2020-04-01       Impact factor: 6.166

2.  The Epstein-Barr virus LMP1 interactome: biological implications and therapeutic targets.

Authors:  Mujeeb R Cheerathodi; David G Meckes
Journal:  Future Virol       Date:  2018-12-03       Impact factor: 1.831

3.  CDKN1A and FANCD2 are potential oncotargets in Burkitt lymphoma and multiple myeloma.

Authors:  Seong-Su Han; Van S Tompkins; Dong-Ju Son; Sangwoo Han; Hwakyung Yun; Natalie L Kamberos; Casey L Dehoedt; Chunyan Gu; Carol Holman; Guido Tricot; Fenghuang Zhan; Siegfried Janz
Journal:  Exp Hematol Oncol       Date:  2015-03-27

4.  Identifying Driver Genomic Alterations in Cancers by Searching Minimum-Weight, Mutually Exclusive Sets.

Authors:  Songjian Lu; Kevin N Lu; Shi-Yuan Cheng; Bo Hu; Xiaojun Ma; Nicholas Nystrom; Xinghua Lu
Journal:  PLoS Comput Biol       Date:  2015-08-28       Impact factor: 4.475

5.  Piperlongumine-induced phosphatidylserine translocation in the erythrocyte membrane.

Authors:  Rosi Bissinger; Abaid Malik; Jamshed Warsi; Kashif Jilani; Florian Lang
Journal:  Toxins (Basel)       Date:  2014-10-14       Impact factor: 4.546

6.  Discovery of piperlongumine as a potential novel lead for the development of senolytic agents.

Authors:  Yingying Wang; Jianhui Chang; Xingui Liu; Xuan Zhang; Suping Zhang; Xin Zhang; Daohong Zhou; Guangrong Zheng
Journal:  Aging (Albany NY)       Date:  2016-11-19       Impact factor: 5.682

7.  Piperlongumine inhibits migration of glioblastoma cells via activation of ROS-dependent p38 and JNK signaling pathways.

Authors:  Qian Rong Liu; Ju Mei Liu; Yong Chen; Xiao Qiang Xie; Xin Xin Xiong; Xin Yao Qiu; Feng Pan; Di Liu; Shang Bin Yu; Xiao Qian Chen
Journal:  Oxid Med Cell Longev       Date:  2014-05-22       Impact factor: 6.543

Review 8.  Anticancer principles from medicinal piper ( hú jiāo) plants.

Authors:  Yue-Hu Wang; Susan L Morris-Natschke; Jun Yang; Hong-Mei Niu; Chun-Lin Long; Kuo-Hsiung Lee
Journal:  J Tradit Complement Med       Date:  2014-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.